Zyversa Therapeutics Stock Fundamentals

ZVSA Stock   0.79  0.01  1.25%   
ZyVersa Therapeutics fundamentals help investors to digest information that contributes to ZyVersa Therapeutics' financial success or failures. It also enables traders to predict the movement of ZyVersa Stock. The fundamental analysis module provides a way to measure ZyVersa Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ZyVersa Therapeutics stock.
At present, ZyVersa Therapeutics' Interest Expense is projected to decrease significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 13.5 B, whereas Net Interest Income is forecasted to decline to (59.4 K).
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

ZyVersa Therapeutics Company Shares Owned By Institutions Analysis

ZyVersa Therapeutics' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

More About Shares Owned By Institutions | All Equity Analysis

Current ZyVersa Therapeutics Shares Owned By Institutions

    
  3.23 %  
Most of ZyVersa Therapeutics' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ZyVersa Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Competition

Based on the latest financial disclosure, 3.232999999999999% of ZyVersa Therapeutics are shares owned by institutions. This is 92.76% lower than that of the Biotechnology sector and 93.19% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 91.75% higher than that of the company.

ZyVersa Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining ZyVersa Therapeutics's current stock value. Our valuation model uses many indicators to compare ZyVersa Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ZyVersa Therapeutics competition to find correlations between indicators driving ZyVersa Therapeutics's intrinsic value. More Info.
ZyVersa Therapeutics is rated below average in return on equity category among its peers. It is rated second in return on asset category among its peers . At present, ZyVersa Therapeutics' Return On Equity is projected to drop based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ZyVersa Therapeutics' earnings, one of the primary drivers of an investment's value.

ZyVersa Shares Owned By Institutions Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ZyVersa Therapeutics' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ZyVersa Therapeutics could also be used in its relative valuation, which is a method of valuing ZyVersa Therapeutics by comparing valuation metrics of similar companies.
ZyVersa Therapeutics is currently under evaluation in shares owned by institutions category among its peers.

ZyVersa Fundamentals

About ZyVersa Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ZyVersa Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ZyVersa Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ZyVersa Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue689.1 K777 K
Cost Of Revenue9.4 K8.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:
Check out ZyVersa Therapeutics Piotroski F Score and ZyVersa Therapeutics Altman Z Score analysis.
For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
491.97
Return On Assets
(0.23)
Return On Equity
(1.60)
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.